Empagliflozin in Heart Failure with a Preserved Ejection Fraction

In a randomized trial, 5988 patients with heart failure with preserved ejection fraction were assigned to receive either empagliflozin or placebo in addition to usual therapy. At a median of 26 months, the empagliflozin group had a lower incidence of cardiovascular death or hospitalization for heart...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 385; no. 16; pp. 1451 - 1461
Main Authors: Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Ferreira, João P, Bocchi, Edimar, Böhm, Michael, Brunner–La Rocca, Hans-Peter, Choi, Dong-Ju, Chopra, Vijay, Chuquiure-Valenzuela, Eduardo, Giannetti, Nadia, Gomez-Mesa, Juan Esteban, Janssens, Stefan, Januzzi, James L, Gonzalez-Juanatey, Jose R, Merkely, Bela, Nicholls, Stephen J, Perrone, Sergio V, Piña, Ileana L, Ponikowski, Piotr, Senni, Michele, Sim, David, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Tsutsui, Hiroyuki, Verma, Subodh, Vinereanu, Dragos, Zhang, Jian, Carson, Peter, Lam, Carolyn Su Ping, Marx, Nikolaus, Zeller, Cordula, Sattar, Naveed, Jamal, Waheed, Schnaidt, Sven, Schnee, Janet M, Brueckmann, Martina, Pocock, Stuart J, Zannad, Faiez, Packer, Milton
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 14.10.2021
Subjects:
Adult
Antidiabetics
Benzhydryl Compounds - administration & dosage
Benzhydryl Compounds - adverse effects
Cardiology
Cardiology and cardiovascular system
Cardiology General
Cardiovascular diseases
Cardiovascular Diseases - mortality
Cardiovascular Diseases - prevention & control
Chronic Disease
Congestive heart failure
Diabetes
Diabetes mellitus
Double-Blind Method
Ejection fraction
Female
Glucosides - administration & dosage
Glucosides - adverse effects
Heart Failure
Heart Failure - drug therapy
Heart Failure - physiopathology
Hospitalization - statistics & numerical data
Human health and pathology
Humans
Hypotension
Life Sciences
Male
Patient safety
Placebos
Sodium-glucose cotransporter
Sodium-Glucose Transporter 2 Inhibitors - administration & dosage
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
Statistical analysis
Stroke Volume
Urinary tract
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a randomized trial, 5988 patients with heart failure with preserved ejection fraction were assigned to receive either empagliflozin or placebo in addition to usual therapy. At a median of 26 months, the empagliflozin group had a lower incidence of cardiovascular death or hospitalization for heart failure than the placebo group.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2107038